Josd2-KO Mouse
一般名
Josd2-KO
製品ID
S-KO-16965
背景情報
C57BL/6JCya
系統ID
KOCMP-66124-Josd2-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Josd2-KO Mouse（カタログ番号S-KO-16965）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Josd2-KO
系統ID
KOCMP-66124-Josd2-B6J-VB
遺伝子名
製品ID
S-KO-16965
遺伝子別名
1110007C05Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 7
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000035844
NCBIトランスクリプトID
NM_025368
ターゲット領域
Exon 3~5
有効領域の大きさ
~2.2 kb
遺伝子研究の概要
Josd2, or Josephin domain-containing protein 2, is a deubiquitinating enzyme (DUB) that plays a crucial role in maintaining the stability of substrate proteins. It is involved in multiple cellular processes through regulating various signaling pathways such as the Wnt, MAPK/ERK, and PI3K/AKT pathways. Its functions are essential in normal cell physiology and are also closely associated with disease development, making genetic models like gene knockout (KO) mice valuable for studying its functions [1-10].
In KO mouse models, Josd2 deficiency aggravated cardiac dysfunction and hypertrophy, indicating its protective role in the heart [1,4]. In NSCLC, depletion of Josd2 significantly impeded tumor growth [2]. In cholangiocarcinoma, the depletion of Josd2 promoted YAP/TAZ proteasomal degradation and inhibited cancer cell proliferation [3]. In acute myeloid leukemia, re-constitution of Josd2 in cells with low expression inhibited cell viability and induced apoptosis [5]. In hepatocellular carcinoma, esophageal squamous cell carcinoma, and breast cancer, down-regulation of Josd2 suppressed tumor-related phenotypes such as cell survival, migration, invasion, and proliferation [6,7,9]. In contrast, in colitis, Josd2 deficiency exacerbated the disease phenotypes by enhancing colon inflammation [8].
In conclusion, Josd2 has diverse functions in different biological processes and disease conditions. Through model-based research, especially KO mouse models, we've learned that Josd2 can act as a tumor promoter in many cancers, while it has a protective role in some non-cancerous diseases like colitis. Understanding Josd2's functions provides potential therapeutic targets for treating hypertrophic cardiomyopathy, various cancers, and inflammatory bowel disease.
References:
1. Han, Jibo, Fang, Zimin, Han, Bingjiang, Wang, Yi, Liang, Guang. 2023. Deubiquitinase JOSD2 improves calcium handling and attenuates cardiac hypertrophy and dysfunction by stabilizing SERCA2a in cardiomyocytes. In Nature cardiovascular research, 2, 764-777. doi:10.1038/s44161-023-00313-y. https://pubmed.ncbi.nlm.nih.gov/39195964/
2. Yuan, Tao, Zeng, Chenming, Liu, Jiawei, He, Qiaojun, Yang, Bo. 2024. Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity. In Signal transduction and targeted therapy, 9, 11. doi:10.1038/s41392-023-01706-y. https://pubmed.ncbi.nlm.nih.gov/38177135/
3. Qian, Meijia, Yan, Fangjie, Wang, Weihua, Zhu, Hong, He, Qiaojun. 2021. Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression. In Acta pharmaceutica Sinica. B, 11, 4008-4019. doi:10.1016/j.apsb.2021.04.003. https://pubmed.ncbi.nlm.nih.gov/35024322/
4. Xu, Jiachen, Liang, Shiqi, Wang, Qinyan, Zhou, Hao, Liang, Guang. 2024. JOSD2 mediates isoprenaline-induced heart failure by deubiquitinating CaMKIIδ in cardiomyocytes. In Cellular and molecular life sciences : CMLS, 81, 18. doi:10.1007/s00018-023-05037-7. https://pubmed.ncbi.nlm.nih.gov/38195959/
5. Lei, Hu, Yang, Li, Wang, Yingying, Xu, Hanzhang, Wu, Yingli. 2022. JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression. In Experimental hematology & oncology, 11, 42. doi:10.1186/s40164-022-00295-w. https://pubmed.ncbi.nlm.nih.gov/35836282/
6. Huang, Yao, Zeng, Jianxing, Liu, Teng, Song, Xianglin, Zeng, Jinhua. 2022. Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradation. In Cell biology international, 46, 1089-1097. doi:10.1002/cbin.11812. https://pubmed.ncbi.nlm.nih.gov/35568970/
7. Wang, Wen-Peng, Shi, Dan, Yun, Duo, Wang, Jun-Feng, Kong, Da-Lu. . Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma. In World journal of gastroenterology, 30, 565-578. doi:10.3748/wjg.v30.i6.565. https://pubmed.ncbi.nlm.nih.gov/38463028/
8. Liu, Xin, Fang, Yi, Huang, Mincong, Wang, Yi, Liang, Guang. 2024. Deubiquitinase JOSD2 alleviates colitis by inhibiting inflammation via deubiquitination of IMPDH2 in macrophages. In Acta pharmaceutica Sinica. B, 15, 1039-1055. doi:10.1016/j.apsb.2024.12.012. https://pubmed.ncbi.nlm.nih.gov/40177575/
9. Du, Jiamin, Wang, Jiao, Ge, Fujing, Yuan, Tao, Zhu, Hong. 2025. JOSD2 promotes breast cancer metastasis by deubiquitinating and stabilizing SMAD4. In Biochemical pharmacology, 232, 116748. doi:10.1016/j.bcp.2025.116748. https://pubmed.ncbi.nlm.nih.gov/39793716/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。